Professor Tomas Deierborg becomes the newest addition to NOSA as senior scientific advisor.
Mr Deierborg is Head of Department at Department of Experimental Medical Science and Research team manager at Neuroinflammation at Lund University.
Tomas is a professor and neuroscientist with a vast experience in clinical research experience and has worked closely with several leading Big Pharma companies.
Tomas brings a wealth of expertise garnered from a distinguished career as a neuroscientist. Renowned for his groundbreaking contributions to the understanding of neurodegenerative diseases such as Alzheimer’s, Stroke, and Parkinson’s, his research has graced the pages of prestigious journals like Nature, capturing the attention of global audiences through coverage in esteemed media outlets like CNN and The New York Times. Notably, he has also steered the helm as CEO of a medtech company, showcasing his versatility and leadership acumen, including leadership awards. With a dedicated focus on unraveling the complexities of neuroinflammation within the brain, Professor Deierborg’s visionary leadership at the Neuroinflammation Lab has been instrumental in driving the translation of pioneering research into clinically tested interventions. Now entrusted with leading a department housing over 70 research groups spanning diverse fields ranging from structural biology and pharmacology to diabetes, lung diseases, neuroscience, vascular research, and bioinformatics, Professor Deierborg stands poised to catalyze innovation and foster interdisciplinary collaboration at NOSA.
We welcome Tomas to the team and look forward to taking the next steps in the NOSA drug delivery project together.
Prof. Tomas Deierborg joins the NOSA advisory board
Professor Tomas Deierborg becomes the newest addition to NOSA as senior scientific advisor.
Mr Deierborg is Head of Department at Department of Experimental Medical Science and Research team manager at Neuroinflammation at Lund University.
Tomas is a professor and neuroscientist with a vast experience in clinical research experience and has worked closely with several leading Big Pharma companies.
Tomas brings a wealth of expertise garnered from a distinguished career as a neuroscientist. Renowned for his groundbreaking contributions to the understanding of neurodegenerative diseases such as Alzheimer’s, Stroke, and Parkinson’s, his research has graced the pages of prestigious journals like Nature, capturing the attention of global audiences through coverage in esteemed media outlets like CNN and The New York Times. Notably, he has also steered the helm as CEO of a medtech company, showcasing his versatility and leadership acumen, including leadership awards. With a dedicated focus on unraveling the complexities of neuroinflammation within the brain, Professor Deierborg’s visionary leadership at the Neuroinflammation Lab has been instrumental in driving the translation of pioneering research into clinically tested interventions. Now entrusted with leading a department housing over 70 research groups spanning diverse fields ranging from structural biology and pharmacology to diabetes, lung diseases, neuroscience, vascular research, and bioinformatics, Professor Deierborg stands poised to catalyze innovation and foster interdisciplinary collaboration at NOSA.
We welcome Tomas to the team and look forward to taking the next steps in the NOSA drug delivery project together.